Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Marinos C. Dalakas MD, FAAN Advisory Board

See All Experts

featured

Published in Neurology and

Journal Scan / Research · March 11, 2021

Inebilizumab Reduces Risk of Attacks in NMOSD

Multiple Sclerosis (Houndmills, Basingstoke, England)

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Kyle Binder MD

Andrew Romeo MD

Multiple Sclerosis (Houndmills, Basingstoke, England)

Sensitivity Analysis of the Primary Endpoint From the N-MOmentum Study of Inebilizumab in NMOSD

Mult. Scler. 2021 Feb 04;[EPub Ahead of Print], BA Cree, JL Bennett, HJ Kim, BG Weinshenker, SJ Pittock, D Wingerchuk, K Fujihara, F Paul, GR Cutter, R Marignier, AJ Green, O Aktas, HP Hartung, IM Williams, J Drappa, D She, D Cimbora, W Rees, JN Ratchford, E Katz

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Multiple Sclerosis

Inebilizumab Reduces Risk of Attacks in NMOSD

Additional Info

Sensitivity Analysis of the Primary Endpoint From the N-MOmentum Study of Inebilizumab in NMOSD

Further Reading

Association of Health and Lifestyle Factors With Dementia Risk in Former Professional Soccer Players

Association of the Cervical Canal Area With Disability and Progression in People With MS

Directional Subthalamic Deep Brain Stimulation Better Improves Gait and Balance Disorders in Patients With Parkinson's Disease

Induction Cyclophosphamide With Maintenance Immunosuppression for High-Risk Myasthenia Gravis

Non-Invasive Continuous Oral Delivery of Solid Levodopa–Carbidopa for the Management of Parkinson's Disease

Low-Frequency Deep Brain Stimulation During Non-REM Sleep Modifies Memory Retention in Patients With Parkinson's Disease

Toward Personalized Dosing of B-Cell–Depleting Therapy

Safety and Efficacy of Intravenous Recombinant Human Prourokinase for Acute Ischaemic Stroke Within 4.5 Hours After Stroke Onset

Hypogammaglobulinemia and Severe Infections in Patients With MS on Anti-CD20 Agents

Risk of Hypertension in Patients With MS Treated With Teriflunomide vs Dimethyl Fumarate

Addition of Cilostazol to Antiplatelet Therapy for In-Stent Restenosis After Carotid Artery Stenting

Recently Updated